Denosumab – an important part of the treatment of patients with skeletal metastatic disease

06/2020

Prof. MUDr. Samuel Vokurka, Ph.D.

Onkologická a radioterapeutická klinika LF UK a FN Plzeň

SUMMARY

Denosumab, 120 mg inj. s.c., significantly contributes to delaying the development of skeletal related events (pathological fracture, spinal cord compression, a condition requiring radiotherapy or surgery to bone) and worsening pain in patients with skeletal metastatic disease. Initial dental care with prophylactic stomatology interventions and proper supplementation of calcium and vitamin D are an integral part and condition for successful treatment with denosumab.

Key words

denosumab, supportive care, metastatic disease, bone, osteonecrosis